HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prolonging action of imidapril on the lifespan expectancy of cardiomyopathic hamsters.

Abstract
We studied the effect of imidapril, a novel angiotensin-converting enzyme (ACE) inhibitor, on lifespan expectancy of cardiomyopathic (CM) hamsters of BIO 14.6 strain, one of the representative models of congestive heart failure (CHF). Imidapril was consecutively administered to hamsters by mixing it in their diet at a concentration of 480 ppm (approximately 30 mg/kg/day) or 1,600 ppm (approximately 120 mg/kg/day) from age 26 weeks. Only several control hamsters died before age 54 weeks, but their survival rate decreased to 23.7% at age 73 weeks. The survival rates of 480-ppm and 1,600-ppm imidapril groups at age 73 weeks were as high as 75.7 and 68.4%, respectively (p < 0.01 vs. control hamsters). Macroscopic and microscopic pathology in imidapril-treated groups was milder than that in control animals in general, but differences were not statistically significant when animals were divided into survivors and fatalities except for the presence of mural thrombus in the heart. We further studied the effects of imidapril on blood pressure (BP), in vivo cardiac function, cardiac beta-adrenoceptor distribution, and plasma catecholamine levels after dietary treatment with 480 ppm imidapril for 8-10 weeks from age 37 weeks. Imidapril-treated animals showed improved cardiac function under urethane anesthesia. These results indicate that imidapril prolongs lifespan expectancy of CM hamsters and suggest that a hemodynamic effect of imidapril is involved in its beneficial effect.
AuthorsH Narita, M Kaburaki, H Doi, N Ogiku, H Yabana, H Kurosawa, Y Ohmachi
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 27 Issue 6 Pg. 861-71 (Jun 1996) ISSN: 0160-2446 [Print] United States
PMID8761854 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Adrenergic beta-Agonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Ethanolamines
  • Imidazoles
  • Imidazolidines
  • Receptors, Adrenergic, beta
  • RP333
  • imidapril
  • Dopamine
  • Norepinephrine
  • Epinephrine
Topics
  • Adrenergic beta-Agonists (pharmacology)
  • Angiotensin-Converting Enzyme Inhibitors (pharmacology, therapeutic use)
  • Animals
  • Cardiomyopathies (drug therapy)
  • Cricetinae
  • Dopamine (blood)
  • Epinephrine (blood)
  • Ethanolamines (pharmacology)
  • Hemodynamics (drug effects)
  • Imidazoles (pharmacology, therapeutic use)
  • Imidazolidines
  • Life Expectancy
  • Liver (pathology)
  • Male
  • Myocardium (metabolism, pathology)
  • Norepinephrine (blood)
  • Receptors, Adrenergic, beta (metabolism)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: